[Form 4] Medpace Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Broadridge Financial Solutions (BR) – Form 4/A insider filing

Director Robert N. Duelks submitted an amended Form 4 detailing a 06/06/2025 transaction. The amendment corrects the original filing to show that the Robert N. Duelks 2007 Revocable Trust—not the director’s direct account—sold 500 common shares at $245.1495 (code “S”).

Post-sale holdings stand at 8,853 BR shares for the trust (indirect ownership “I”) and 20,358 shares held directly by Duelks. No derivative securities or additional transactions were reported.

The update improves disclosure accuracy but also confirms a modest insider sale.

Positive

• Improved transparency: Amendment clarifies that shares were sold by the revocable trust, enhancing accuracy of insider ownership records.

Negative

• Insider sale: Director-related trust disposed of 500 shares, a modest but negative sentiment indicator.
• Prior misreporting: Original Form 4 contained an ownership classification error requiring correction.

Insights

Financial Analyst

TL;DR: Small trust sale; corrective filing; immaterial to BR valuation—neutral impact.

The transaction involves only 500 shares, a negligible portion of Broadridge’s float and of Duelks’ combined 29,211-share stake. Because the stock was sold by a revocable trust, it likely reflects personal portfolio management rather than a signal on fundamentals. The amendment removes a classification error, restoring clarity to insider ownership data. No change to earnings outlook, liquidity, or capital structure; therefore I view the market impact as neutral.

Corporate Governance Expert

TL;DR: Filing corrects ownership misstatement; transparency improved, but initial error is a governance blemish.

Section 16 compliance requires precise disclosure. The original misclassification—direct versus indirect holding—was promptly fixed, limiting regulatory risk. While the 500-share sale is minor, the need for an amendment highlights the importance of robust internal controls over insider reporting. Investors should monitor for repeat errors, yet one isolated correction is unlikely to sway governance assessments materially.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Brady Kevin M.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2025		M		12,000	A	$57.94	18,000	D
Common Stock	07/24/2025		S(1)		12,000	D	$454.23(2)	6,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$57.94	07/24/2025		M			12,000	(3)	11/12/2025	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $449.25 to $461.24. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The option vested in full on November 12, 2022.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Kevin M. Brady	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Broadridge (BR) shares did Robert Duelks' trust sell on 06/06/2025?

The Form 4/A reports a sale of 500 common shares by the Robert N. Duelks 2007 Revocable Trust.

At what price were the Broadridge shares sold?

The shares were sold at $245.1495 per share.

How many BR shares does the trust own after the sale?

Following the transaction, the trust owns 8,853 shares indirectly.

Why was the Form 4 amended?

The amendment corrects the earlier filing, showing the sale came from the revocable trust rather than Duelks’ direct holdings.

What are Robert Duelks’ direct holdings in Broadridge after the amendment?

He continues to hold 20,358 shares directly, unchanged by this filing.